Lesley S Park1, Kathleen A McGinnis2, Kirsha S Gordon2,3, Amy C Justice2,3,4, Wendy Leyden5, Michael J Silverberg5, Jacek Skarbinski5, Celeena Jefferson6, Michael Horberg6, Julia Certa6, Sonia Napravnik7, Jessie K Edwards7, Daniel Westreich7, Lisa Bastarache8, Srushti Gangireddy8, Lorie Benning9, Gypsyamber D'Souza9, Carolyn Williams10, Keri N Althoff9. 1. Center for Population Health Sciences, Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA. 2. Department of Internal Medicine, VA Connecticut Healthcare, West Haven, CT. 3. Yale University School of Medicine, New Haven, CT. 4. Yale University School of Public Health New Haven, CT. 5. Division of Research, Kaiser Permanente Northern California, Oakland, CA. 6. Kaiser Permanente Mid-Atlantic Permanente Research Institute, Rockville, MD. 7. Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC. 8. Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN. 9. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; and. 10. Epidemiology Branch, Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, MD.
Abstract
BACKGROUND: It is not definitively known if persons with HIV (PWH) are more likely to be SARS-CoV-2 tested or test positive than persons without HIV (PWoH). We describe SARS-CoV-2 testing and positivity in 6 large geographically and demographically diverse cohorts of PWH and PWoH in the United States. SETTING: The Corona Infectious Virus Epidemiology Team comprises 5 clinical cohorts within a health system (Kaiser Permanente Northern California, Oakland, CA; Kaiser Permanente Mid-Atlantic States, Rockville, MD; University of North Carolina Health, Chapel Hill, NC; Vanderbilt University Medical Center, Nashville, TN; and Veterans Aging Cohort Study) and 1 interval cohort (Multicenter AIDS Cohort Study/Women's Interagency HIV Study Combined Cohort Study). METHODS: We calculated the proportion of patients SARS-CoV-2 tested and the test positivity proportion by HIV status from March 1 to December 31, 2020. RESULTS: The cohorts ranged in size from 1675 to 31,304 PWH and 1430 to 3,742,604 PWoH. The proportion of PWH who were tested for SARS-CoV-2 (19.6%-40.5% across sites) was significantly higher than PWoH (14.8%-29.4%) in the clinical cohorts. However, among those tested, the proportion of patients with positive SARS-CoV-2 tests was comparable by HIV status; the difference in proportion of SARS-CoV-2 positivity ranged from 4.7% lower to 1.4% higher. CONCLUSIONS: Although PWH had higher testing proportions compared with PWoH, we did not find evidence of increased positivity in 6 large, diverse populations across the United States. Ongoing monitoring of testing, positivity, and COVID-19-related outcomes in PWH are needed, given availability, response, and durability of COVID-19 vaccines; emergence of SARS-CoV-2 variants; and latest therapeutic options.
BACKGROUND: It is not definitively known if persons with HIV (PWH) are more likely to be SARS-CoV-2 tested or test positive than persons without HIV (PWoH). We describe SARS-CoV-2 testing and positivity in 6 large geographically and demographically diverse cohorts of PWH and PWoH in the United States. SETTING: The Corona Infectious Virus Epidemiology Team comprises 5 clinical cohorts within a health system (Kaiser Permanente Northern California, Oakland, CA; Kaiser Permanente Mid-Atlantic States, Rockville, MD; University of North Carolina Health, Chapel Hill, NC; Vanderbilt University Medical Center, Nashville, TN; and Veterans Aging Cohort Study) and 1 interval cohort (Multicenter AIDS Cohort Study/Women's Interagency HIV Study Combined Cohort Study). METHODS: We calculated the proportion of patients SARS-CoV-2 tested and the test positivity proportion by HIV status from March 1 to December 31, 2020. RESULTS: The cohorts ranged in size from 1675 to 31,304 PWH and 1430 to 3,742,604 PWoH. The proportion of PWH who were tested for SARS-CoV-2 (19.6%-40.5% across sites) was significantly higher than PWoH (14.8%-29.4%) in the clinical cohorts. However, among those tested, the proportion of patients with positive SARS-CoV-2 tests was comparable by HIV status; the difference in proportion of SARS-CoV-2 positivity ranged from 4.7% lower to 1.4% higher. CONCLUSIONS: Although PWH had higher testing proportions compared with PWoH, we did not find evidence of increased positivity in 6 large, diverse populations across the United States. Ongoing monitoring of testing, positivity, and COVID-19-related outcomes in PWH are needed, given availability, response, and durability of COVID-19 vaccines; emergence of SARS-CoV-2 variants; and latest therapeutic options.
Authors: Stephen J Gange; Mari M Kitahata; Michael S Saag; David R Bangsberg; Ronald J Bosch; John T Brooks; Liviana Calzavara; Steven G Deeks; Joseph J Eron; Kelly A Gebo; M John Gill; David W Haas; Robert S Hogg; Michael A Horberg; Lisa P Jacobson; Amy C Justice; Gregory D Kirk; Marina B Klein; Jeffrey N Martin; Rosemary G McKaig; Benigno Rodriguez; Sean B Rourke; Timothy R Sterling; Aimee M Freeman; Richard D Moore Journal: Int J Epidemiol Date: 2007-01-08 Impact factor: 7.196
Authors: James M Tesoriero; Carol-Ann E Swain; Jennifer L Pierce; Lucila Zamboni; Meng Wu; David R Holtgrave; Charles J Gonzalez; Tomoko Udo; Johanne E Morne; Rachel Hart-Malloy; Deepa T Rajulu; Shu-Yin John Leung; Eli S Rosenberg Journal: JAMA Netw Open Date: 2021-02-01
Authors: Krishnan Bhaskaran; Christopher T Rentsch; Brian MacKenna; Anna Schultze; Amir Mehrkar; Chris J Bates; Rosalind M Eggo; Caroline E Morton; Sebastian C J Bacon; Peter Inglesby; Ian J Douglas; Alex J Walker; Helen I McDonald; Jonathan Cockburn; Elizabeth J Williamson; David Evans; Harriet J Forbes; Helen J Curtis; William J Hulme; John Parry; Frank Hester; Sam Harper; Stephen J W Evans; Liam Smeeth; Ben Goldacre Journal: Lancet HIV Date: 2020-12-11 Impact factor: 12.767
Authors: Georg Härter; Christoph D Spinner; Julia Roider; Markus Bickel; Ivanka Krznaric; Stephan Grunwald; Farhad Schabaz; Daniel Gillor; Nils Postel; Matthias C Mueller; Markus Müller; Katja Römer; Knud Schewe; Christian Hoffmann Journal: Infection Date: 2020-05-11 Impact factor: 3.553
Authors: Christopher T Rentsch; Farah Kidwai-Khan; Janet P Tate; Lesley S Park; Joseph T King; Melissa Skanderson; Ronald G Hauser; Anna Schultze; Christopher I Jarvis; Mark Holodniy; Vincent Lo Re; Kathleen M Akgün; Kristina Crothers; Tamar H Taddei; Matthew S Freiberg; Amy C Justice Journal: PLoS Med Date: 2020-09-22 Impact factor: 11.069
Authors: Gypsyamber D'Souza; Gayle Springer; Deborah Gustafson; Seble Kassaye; Maria L Alcaide; Catalina Ramirez; Anjali Sharma; Frank J Palella; Phyllis C Tien; Roger Detels; Mirjam-Colette Kempf; Cecile D Lahiri; Charles R Rinaldo; Audrey L French; Joseph B Margolick; Ada A Adimora Journal: HIV Res Clin Pract Date: 2020-11-19
Authors: Pontus Hedberg; Jan Vesterbacka; Ola Blennow; Catharina Missailidis; Piotr Nowak; Pontus Naucler Journal: J Intern Med Date: 2022-03-21 Impact factor: 13.068